Although it was reported that p53 mutations can be a prerequisite for 5-aza-C-induced sensitization to SN-38, an active metabolite of irinotecan [41], we found that 5-azanucleosides sensitize both p53-mutated and wild-type (wt) p53-expressing CRC cells to topoisomerase inhibitors (Table 1). The gene discussed is TP53; the disease is colorectal carcinoma.